Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of Buy from Brokerages – Defense World

Posted: May 15, 2022 at 1:58 am

Jasper Therapeutics, Inc. (NASDAQ:JSPR Get Rating) has been given a consensus recommendation of Buy by the six analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $15.00.

JSPR has been the subject of several recent research reports. Credit Suisse Group cut their price target on Jasper Therapeutics from $15.00 to $10.00 and set an outperform rating for the company in a report on Friday, February 25th. Cantor Fitzgerald initiated coverage on Jasper Therapeutics in a report on Monday, February 28th. They set an overweight rating and a $10.00 price target for the company. Finally, Zacks Investment Research raised Jasper Therapeutics from a sell rating to a hold rating in a report on Thursday, January 20th.

Shares of JSPR traded up $0.06 during trading hours on Friday, hitting $2.99. The stock had a trading volume of 20,735 shares, compared to its average volume of 72,180. Jasper Therapeutics has a 12 month low of $2.45 and a 12 month high of $18.88. The stock has a fifty day moving average price of $3.19 and a 200 day moving average price of $5.61.

Jasper Therapeutics Company Profile (Get Rating)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.

Featured Articles

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read the rest here:
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of Buy from Brokerages - Defense World

Related Posts